Short-Term Outcomes After Intravitreal Injections of Conbercept Versus Ranibizumab for the Treatment of Retinopathy of Prematurity

Abstract

Both conbercept and ranibizumab are effective choice for the treatment of ROP. Conbercept is a novel effective treatment strategy for ROP providing a new treatment option for ophthalmologists.

Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity

“…Our inclusion criteria are broader than the screening guideline recommendations in the USA (GA <30 weeks, BW <1500 g) and UK (GA <32 weeks, BW <1500 g)1 22 because severe ROP occurs in more mature and larger infants in China 23 24. The mean PMA for the time of first IVC is 34.2±1.9 weeks and 5.8±1.4 weeks, which is in accordance with 36.6±3.2 PMA by Wu et al and 36.0±2.34 PMA by Huang et al in the study of bevacizumab and ranibizumab treatment for infants with ROP, respectively,25 but slightly earlier than the 38.47±2.72 weeks reported by Jin et al 26. We found that using an IVC injection once, as monotherapy, resulted in the regression of plus disease without recurrence in 83.7% (40/48) of eyes with type 1 ROP and AP-ROP.…”

“…We found that using an IVC injection once, as monotherapy, resulted in the regression of plus disease without recurrence in 83.7% (40/48) of eyes with type 1 ROP and AP-ROP. This result bore a resemblance to the recently reported regression rate of 85% by Jin et al 26. Similarly, the regression rates are 83.3% by the bevacizumab treatment and 79.5% by ranibizumab treatment, respectively 2 10 21…”

Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity

“…Y.) according to our preferred technique as previously described [10]. e clinical data and fluorescein angiograms were collected during routine care of the children.…”

“…But the side effect of this treatment including visual field loss caused by permanent ablation of the hypoxic retina and subsequent high myopia should not be ignored [7,8]. e off-label intravitreal injection of anti-VEGF agents such as conbercept (KH902; Chengdu Kanghong Biotech Co, Ltd, Sichuan, China), bevacizumab (Genentech, Inc, South San Francisco, CA), ranibizumab (Genentech, Inc and Novartis International AG, Basel, Switzerland), and aflibercept (Regeneron Pharmaceuticals Inc) for ROP treatment has been reported in recent years and shown to be efficacious [9][10][11][12][13]. For most ROP infants, anti-VEGF drugs could effectively improve the structural outcomes in no shorter than 6-month follow-up period although some recurrences may occur in 2.8%-35.7% of them [9][10][11][12][13].…”

“…But until now, no study has reported the FA outcomes of ROP for infants treated with intravitreal injection of conbercept (IVC). Conbercept is a recombinant fusion protein composed of the second Ig domain of VEGFR1 and the third and fourth Ig domains of VEGFR2 to the constant region (Fc) of human IgG1 and has been approved by the China Food and Drug Administration (CFDA) for intraocular application [10].…”